Oliclinomel N4-550 E (Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin)

Oliclinomel N4-550 E is used primarily for amino‑acid supplementation in clinical situations that affect protein metabolism:

• Post‑operative recovery: helps to promote recovery by providing the building blocks of protein synthesis in the post‑surgical patient.
• Severe malnutrition: assists in restoring nitrogen balance and support of muscle mass when dietary intake is insufficient.
• Inherited metabolic disorders such as phenylketonuria (PKU) or other branched‑chain amino‑acid deficiencies where target amino‑acid profiles are required to manage the disorder.
• Critical‑illness ICU care: provides targeted amino‑acid support to critically ill patients to maintain lean body tissue and immune function.
• Liver disease and hepatic failure in patients with impaired protein synthesis and in need of amino‑acid replacement for nutrition support .

• Oliclinomel N4-550 E supplies a defined blend of amino acids that are directly incorporated into protein synthesis pathways. The administered amino acids bypass gastrointestinal digestion, entering the bloodstream where they serve as substrates for ribosomal assembly of proteins, support nitrogen balance, and modulate metabolic signaling pathways such as mTOR, which regulates cell growth and tissue repair.

Adverse reactions to Oliclinomel N4-550 E are generally mild and related to the intravenous route.

Common Side Effects

• Injection site erythema: mild redness of the injection site.
• Transient headache : temporary headache during or after infusion.
• Nausea: occasional feeling of queasiness or vomiting .
• Mild hyperglycemia: slight increase in blood glucose levels.
• Electrolyte shift : minor changes in serum potassium or sodium levels.

Serious or Rare Side Effects

• Anaphylactic reaction: severe, potentially life‑threatening allergic response.
• Acute renal failure : rapid decline in kidney function requiring intervention.
• Severe hyperammonemia: marked increase in blood ammon levels that can affect brain function.
• Thrombotic events : blood clot formation in veins or arteries.
• Metabolic acidosis : significant acid‑base imbalance requiring medical management.

When using Oliclinomel N4-550 E, clinicians should consider several safety measures:

• Renal function monitoring: assess the patient for renal impairment before and during therapy.
• Hepatic function assessment: evaluate liver status to avoid exacerbation of metabolic disorders.
• Electrolyte balance: check serum electrolytes regularly, especially potassium and sodium.
• Allergic history: verify any previous allergic reactions to amino‑acid solutions.
• Metabolic monitoring: observe for signs of hyperammonemia or acid‑base disturbances.
• Store at ambient temperature: keep the powder in its original container away from moisture.

Oliclinomel N4-550 E may interact with other therapies that affect amino‑acid metabolism or renal clearance:

Major Interactions (Avoid)

• High‑dose glutamine supplementation: may increase nitrogen load and risk of hyperammonemia.
• Nephrotoxic antibiotics: concurrent use can worsen renal impairment.

Moderate Interactions (Monitor Closely)

• Insulin or oral hypoglycemic agents: may require dose adjustment due to transient hyperglycemia.
• Diuretics: can alter electrolyte balance when combined with amino‑acid infusion.
• Parenteral lipid‑emulsion of the same formulation : risk of incompatibility in Y‑Y mixing devices.
• Citrate c